Log in to search using one of your social media accounts:

 

Clinical Decision-Making for Immunotherapy in Metastatic RCC Clinical Decision-Making for Immunotherapy in Metastatic RCC
Should immunotherapy be considered as a first-line treatment strategy for metastatic renal cell carcinoma?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Videos:2017 Kidney Cancer Association Patient & Survivor Conference
Conclusions.01/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - January 9, 2018 Category: Urology & Nephrology Source Type: news

Do more CT scans lead to more kidney surgeries?
The higher the number of chest or abdominal CT exams in a hospital referral...Read more on AuntMinnie.comRelated Reading: Incidental imaging findings boost healthcare costs Incidental findings: When in doubt, point them out -- or not Incidental findings on CT lung screening offer benefits, costs Incidental findings on CT spark disagreement CT tracks renal cancer recurrence after surgery (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 9, 2018 Category: Radiology Source Type: news

Lymphadenectomy in Renal Cell Carcinoma: No Benefit? Lymphadenectomy in Renal Cell Carcinoma: No Benefit?
A secondary analysis of the ASSURE trial reveals that lymph node removal does not improve survival in high-risk renal cell carcinoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

'Is Ian cured? Maybe': the astonishing cancer treatment of Australia's chief scientist
Ian Chubb was diagnosed with metastatic kidney cancer and his prognosis was grim. But now, as far as his oncologist can tell, he is cancer-free“One of my kids said to me it was the first time in their life they saw me scared,” says Ian Chubb, recalling a time he found himself almost unable to breathe after walking for just a few dozen metres.Perhaps more than any other living Australian, Chubb has dedicated his life to championing science.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 1, 2018 Category: Science Authors: Michael Slezak Tags: Cancer research Science Health Australia news Medical research Source Type: news

Aveo, former execs reach $15M settlement with shareholders over 2013 drug rejection
Investors had accused the Cambridge biotech and the former executives of concealing issues with a kidney cancer drug before it was rejected. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 27, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Aveo, former execs reach $15M settlement with shareholders over 2013 drug rejection
Investors had accused the Cambridge biotech and the former executives of concealing issues with a kidney cancer drug before it was rejected. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 27, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
"A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer..."01/02/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 22, 2017 Category: Urology & Nephrology Source Type: news

New class of anti-cancer drug effective against kidney cancer
(UT Southwestern Medical Center) A study published in the Journal of Clinical Oncology reports initial findings with a novel drug belonging to a new class of medicines called HIF-2a inhibitors that show promise in treating metastatic kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news

Still got talent
When David Shutts was treated for advanced kidney cancer nothing hurt him more than being jobless - so he decided to do something about it. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 20, 2017 Category: Consumer Health News Source Type: news

U.S. FDA Approval of CABOMETYX ® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults.12/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 20, 2017 Category: Urology & Nephrology Source Type: news

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2017-- Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx (cabozantinib) tablets for the expanded indication of patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 19, 2017 Category: Drugs & Pharmacology Source Type: news

Results from Alliance CABOSUN trial lead to US FDA approval of extended indication
(Alliance for Clinical Trials in Oncology) The Alliance for Clinical Trials in Oncology (the Alliance), in conjunction with industry partner Exelixis, today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX ® (cabozantinib) tablets for the expanded indication of patients with advanced renal cell carcinoma (RCC). RCC is the most common form of kidney cancer in adults. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 19, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Eisai ’s Kisplyx for renal cell carcinoma
Eisai Oncology business group EMEA chairman and CEO Gary Hendler said: “We are delighted that NICE is recommending lenvatinib in combination with everolimus for routine access to adult patients for the treatment of advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.12/14/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 13, 2017 Category: Urology & Nephrology Source Type: news

Phase III IMmotion151 Study Met Co-primary Goal In Kidney Cancer
The study demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death...12/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 12, 2017 Category: Urology & Nephrology Source Type: news

Roche: Tecentriq cocktail slows kidney cancer progression
ZURICH (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2017 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche ’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer
Roche today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) in people whose disease expressed the PD-L1 (programmed death-ligand 1: Expression ≥1%) protein compared with sunitinib for the fir st-line treatment of people who have advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 11, 2017 Category: Pharmaceuticals Source Type: news

Dr. Escudier: The Future of RCC Treatment
Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. He is a member of the Kidney Cancer Association Professional Group and formerly a member of its Medical& Scientific Steering Committee. His research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutics.12/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 7, 2017 Category: Urology & Nephrology Source Type: news

Preoperative Cholesterol Level Is Associated With Worse Pathological Outcomes
In this study, we aimed to investigate the relationship between preoperative cholesterol level (PCL) and postoperative outcomes of patients with localized RCC.12/06/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 6, 2017 Category: Urology & Nephrology Source Type: news

“I need to go to the doctor,” Quiet 5-year-old girl knew something was wrong
Reese Park is working toward a day with no training wheels outside her Bridge Creek home. The 5-year-old is biking with her siblings, which includes quite a crew since she's the second oldest of six children. Reese's parents describe her as strong and quiet, so she seemed very out of character last July when she told her dad she needed medical help right away.12/06/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 6, 2017 Category: Urology & Nephrology Source Type: news

NICE recommends lenvatinib for kidney cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Adjuvant Therapy for Renal Cell Carcinoma
The FDA has approved sunitinib malate (Sutent) as an adjuvant therapy for adults at risk for recurrent renal cell carcinoma following nephrectomy. Sunitinib, a kinase... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news

FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.11/30/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 19, 2017 Category: Urology & Nephrology Source Type: news

FDA OKs First Adjuvant Treatment for Kidney Cancer FDA OKs First Adjuvant Treatment for Kidney Cancer
Sunitinib is now approved for use after surgery in renal cell carcinoma patients who are at high risk for disease recurrence.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA expands approval for Pfizer cancer drug Sutent
(Reuters) - The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. (Source: Reuters: Health)
Source: Reuters: Health - November 16, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA expands approval of Sutent to reduce the risk of kidney cancer returning
FDA approves first adjuvant treatment for adult patients who are at a high risk of kidney cancer returning after a kidney has been removed. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 16, 2017 Category: American Health Source Type: news

FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 16, 2017 -- The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2017 Category: Drugs & Pharmacology Source Type: news

Pfizer receives FDA approval for SUTENT ® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Kidney cancer gene discovery: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, we hear how genetics continues to play a larger role in the fight against kidney cancer. To listen, click the link below. Kidney Cancer Gene Discovery (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - November 15, 2017 Category: Databases & Libraries Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

It Takes All of Us ” Casino Royale - Kidney Cancer Awareness Gala
The Dennis C. Baylor“BIG LUV” Kidney Cancer Foundation is proud to Announce that we will be hosting an elegant Evening with a purpose.Theme:“It Takes All of Us” Casino Royale - Kidney Cancer Awareness Gala to beheld:Friday November 24, 2017 at The Venue located at 10 Tallmadge Circle,Tallmadge OH 44278 - 8:00pm-1:00am This“Orange is The New Black” Semi-Formal event will feature Open Bar,Silent and Live auctions, Chef/Staff and entertainment. Guests will see a video tribute in memory of Dennis Baylor as well as hear inspirational storiesfrom kidney patients, caregivers, kidney d...
Source: Kidney Cancer Association - October 31, 2017 Category: Urology & Nephrology Source Type: news

Request for Proposals (RFP): Kidney Cancer Young Investigator Award (YIA)
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017. The YIA is a one-year research grant totaling $50,000, which is paid in two equal installments to the awardee’s institution. Its aim is to provide funding to promising investigators to encourage and promote quality research in urology and clinical oncology. The awards given are based on individual merit and availability of funds. An applicant must have attained a postgraduate degree or a doctoral degree...
Source: Kidney Cancer Association - October 30, 2017 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Request for Proposals (RFP)
Kidney Cancer Young Investigator Award (YIA)(PRWeb October 30, 2017)Read the full story at http://www.prweb.com/releases/2017/10/prweb14857468.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 30, 2017 Category: Pharmaceuticals Source Type: news

CDMRP:Transforming Healthcare through Innovative and Impactful Research
Kidney Cancer Research (KCRP) has been funded by the CDMRP for many years under various programs including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and, most recently, by the Peer Reviewed Cancer Research Program (PRCRP). From FY10 through FY16, the PRCRP invested over $9.8M in kidney cancer research. In FY17 the US Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program.10/28/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 28, 2017 Category: Urology & Nephrology Source Type: news

Request for Proposals (RFP): Kidney Cancer Young Investigator Award (YIA)
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017. The YIA is a one-year research grant totaling $50,000, which is paid in two equal installments to the awardee’s institution. Its aim is to provide funding to promising investigators to encourage and promote quality research in urology and clinical oncology. The awards given are based on individual merit and availability of funds. An applicant must have attained a postgraduate degree or a doctoral degree...
Source: Kidney Cancer Association - October 28, 2017 Category: Urology & Nephrology Source Type: news

UT Health San Antonio researchers define mechanism that causes kidney cancer to recur
(University of Texas Health Science Center at San Antonio) Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and US Department of Veterans Affairs have identified the molecular mechanism causing kidney cancer to resist drug treatment. The findings were published in the journal Nature Communications. They discovered NOX4, an enzyme in the cell's mitochondria, senses the Warburg effect (movement of adenosine triphosphate's energy production from inside to outside the mitochondria), and switches on to initiate drug resistance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Study indicates arsenic can cause cancer decades after exposure ends
(Oxford University Press USA) A new paper published in the Journal of the National Cancer Institute shows that arsenic in drinking water may have one of the longest dormancy periods of any carcinogen. By tracking the mortality rates of people exposed to arsenic-contaminated drinking water in a region in Chile, the researchers provide evidence of increases in lung, bladder, and kidney cancer even 40 years after high arsenic exposures ended. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2017 Category: International Medicine & Public Health Source Type: news

Kidney cancer breakthrough: THIS could be why more men than women suffer from symptoms
KIDNEY cancer is more prevalent in men, and researchers believe male sex hormones could be the reason why. (Source: Daily Express - Health)
Source: Daily Express - Health - October 17, 2017 Category: Consumer Health News Source Type: news

Study Reveals Complex Biology, Gender Differences, in Kidney Cancer
A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 13, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Study reveals complex biology, gender differences, in kidney cancer
(University of Rochester Medical Center) A new study is believed to be the first to describe the unique role of androgens in kidney cancer, and it suggests that a new approach to treatment, targeting the androgen receptor (AR), is worth further investigation. The study shows that in renal cell carcinoma androgen signaling can either stimulate or suppress tumor cells' movement and invasion to different locations in the body. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 13, 2017 Category: Cancer & Oncology Source Type: news

Important support services at the fingertips of cancer patients
“Today, more than 15 million people in the United States are living with cancer and that number is expected to grow as emerging science and better therapies are likely to increase the number of patients living with cancer as we strive for a cure..."10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 10, 2017 Category: Urology & Nephrology Source Type: news

Novel programs to put important support services at the fingertips of cancer patients
“Today, more than 15 million people in the United States are living with cancer and that number is expected to grow as emerging science and better therapies are likely to increase the number of patients living with cancer as we strive for a cure..."10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 7, 2017 Category: Urology & Nephrology Source Type: news

Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence
Adjuvant treatment of renal-cell carcinoma (RCC) after nephrectomy with sunitinib has produced no increase in overall survival, but the treatment results in less distant disease recurrence and a higher rate of disease-free survival, according to the latest data from the S-TRAC study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Wanted: 1 million people to study genes, habits and health
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact...10/05/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 5, 2017 Category: Urology & Nephrology Source Type: news

Dana Farber/Harvard Kidney Cancer Symposium
10th Annual Dana Farber/Harvard Cancer Center Kidney Cancer Symposium 09/28/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 28, 2017 Category: Urology & Nephrology Source Type: news

Will You Answer This Question? It Will Help To Determine The Future Of Patient Education
We're seeking your input on the planning of a large patient education meeting that would span two days and include presentations from leading experts from the major institutions...10/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 24, 2017 Category: Urology & Nephrology Source Type: news

Southern Cancer Center is Global Leader in Kidney Cancer Clinical Trial
Mobile, Ala. (September 19, 2017) - Southern Cancer Center (SCC), a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients. (Source: McKesson News)
Source: McKesson News - September 19, 2017 Category: Information Technology Source Type: news

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Department of Defense Kidney Cancer Research Program
The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).09/30...
Source: Kidney Cancer Association - September 14, 2017 Category: Urology & Nephrology Source Type: news